VDR and breast cancer: Intriguingly, while the aforementioned effects seem to be independent of the TP53 gene, a study has proposed that mutant p53 protein interacts physically with VDR in breast cancer cells, converting the ligand into an anti-apoptotic agent by mechanisms that remain unclear [167].